| 產品編號 | bs-7110R |
| 英文名稱 | Rabbit Anti-DOCK1 antibody |
| 中文名稱 | 細胞質分裂付出蛋白1抗體 |
| 別 名 | 180 kDa protein downstream of CRK; Ced5; Dedicator of Cytokinesis 1; Dedicator of cytokinesis protein 1; DOCK 1; DOCK-1; DOCK 180; DOCK1; DOCK1_HUMAN; DOCK180. |
| 研究領域 | 腫瘤 細胞生物 信號轉導 細胞凋亡 細胞自噬 G蛋白信號 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Mouse (predicted: Human,Rat,Sheep,Cow,Chicken,Dog,Horse) |
| 產品應用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 215kDa |
| 細胞定位 | 細胞漿 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human DOCK1: 465-550/1865 |
| 亞 型 | |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Functions as a guanine nucleotide exchange factor (GEF), which activates Rac Rho small GTPases by exchanging bound GDP for free GTP. Its GEF activity may be enhanced by ELMO1. Tissue specificity: Highly expressed in placenta, lung, kidney, pancreas and ovary. Expressed at intermediate level in thymus, testes and colon. Function: Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Functions as a guanine nucleotide exchange factor (GEF), which activates Rac Rho small GTPases by exchanging bound GDP for free GTP. Its GEF activity may be enhanced by ELMO1. Subunit: Interacts with the SH3 domains of CRK and NCK2 via multiple sites. Interacts with nucleotide-free RAC1 via its DHR-2 domain. Interacts with ELMO1, ELMO2 and probably ELMO3 via its SH3 domain. Interacts with RAC1 and BAI1. Subcellular Location: Cytoplasm (Probable). Membrane (Probable). Note=Recruited to membranes via its interaction with phosphatidylinositol 3,4,5-trisphosphate (Probable). Tissue Specificity: Highly expressed in placenta, lung, kidney, pancreas and ovary. Expressed at intermediate level in thymus, testes and colon. Similarity: Belongs to the DOCK family. Contains 1 DHR-1 domain. Contains 1 DHR-2 domain. Contains 1 SH3 domain. SWISS: Q14185 Gene ID: 1793 Database links: Entrez Gene: 1793 Human Entrez Gene: 330662 Mouse Omim: 601403 Human SwissProt: Q14185 Human SwissProt: Q8BUR4 Mouse Unigene: 159195 Human Unigene: 645702 Human Unigene: 436572 Mouse ????????????????????????????????????乳腺癌轉移的新標記物DOCK1 ????乳腺癌是一種常常發生轉移的癌癥。將近90%的乳腺癌患者都因為癌癥擴散而死，因此，理解這一危險過程的細胞和分子基礎機制是十分重要的。 ????近日，加拿大蒙特利爾臨床研究所（Institut de recherches cliniques de Montreal, IRCM）的科學家在乳腺癌研究方面取得了一個重要的發現，他們確定了，一種名為DOCK1的蛋白質可以作為潛在的靶標用于減少乳腺癌患者的癌轉移。相關研究結果刊登在了近期出版的《PNAS》上。 ????研究人員在乳腺癌治療方面盡管已經取得了重要的進展，但是對于癌癥擴散的機制卻知之甚少。科學家正在試圖確定能夠調節癌轉移過程的蛋白質，因為它們或許可以作為新的藥物靶標，并與現有的方法相結合促進治療的效果。 ????在這項研究中，2個主要的癌癥亞型——HER-2+型和Basal-like型，很容易轉移和復發，并最終導致患者的低生存率。該調查以HER-2+(人類表皮生長因子受體2)型為研究對象， 這代表了大約25%的乳腺癌病例。 HER2陽性腫瘤比其它類型的腫瘤更傾向于快速的發展和擴散。 ????研究人員解釋到，通過研究HER2+乳腺癌小鼠模型，確定了DOCK1蛋白質是癌轉移的一個重要的調控因子。當去除了小鼠中的這一蛋白質后，乳腺癌的肺轉移大大減少了。此外，研究發現DOCK1蛋白質有助于腫瘤的生長。 ????為了證明DOCK1的表達與乳腺癌預后之間的關系，研究人員對包含患者基因信息的幾個數據庫進行了分析。結果發現，在HER-2+型或Basal-like型乳腺癌中，高水平的DOCK1與較差的預后以及疾病的復發有關。 |
| 產品圖片 |
Paraformaldehyde-fixed, paraffin embedded (Mouse testis); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (DOCK1) Polyclonal Antibody, Unconjugated (bs-7110R) at 1:500 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
